Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Honeywell International Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.95 (market cap $4.59B), while Honeywell International Inc trades at $207.1 (market cap $65.48B). The key difference: Honeywell International Inc is far larger — about 14.3× Definium Therapeutics Inc. Common Shares's market cap, and Honeywell International Inc pays a 1.36% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Honeywell International Inc for 90 Days on average.
| DFTX | HON | |
|---|---|---|
Market Cap | $4.59B | $65.48B |
Volume | 2,103,937 | 2,047,782 |
Sector | Health | Industrials |
52-Week High | $48.45 | $248.79 |
52-Week Low | $10.68 | $188.14 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $3.55B | $90.27B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal despite strong fundamentals including a P/E of 8 and robust profitability margins. The company has beaten earnings estimates for three consecutive quarters and maintains a 66.7% analyst buy rating with a $259.25 consensus price target. Recent corporate developments include a $300 million refinery project win and quarterly dividend payments of $0.70 per share.
The outlook remains positive given HON's earnings momentum and strategic focus on automation post-spinoff, though technical weakness and rising debt-to-asset ratios pose near-term risks. Wall Street optimism is supported by strong profitability metrics and recent contract wins, while investors should monitor execution of the company's transformation strategy and macroeconomic pressures on industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
